The STAMPEDE trial has received the '2017 David Sackett Trial of the Year Award' from the Society for Clinical Trials (SCT). Each year since 2008, the SCT has presented the award to the randomized clinical trial published in the previous year that best fulfils exacting standards. The trial must provide the basis for a substantial, beneficial change in healthcare, reflect expertise, methodological excellence, and concern for its participants. The trial's design, execution, and results must be a model of clarity and intellectual soundness. The international award was presented at the 39th SCT Annual Meeting held 20-23 May 2018, in Portland, Oregon. Professor Mahesh Parmar, Director of MRC CTU at UCL and the UCL Institute of Clinical Trials and Methodology, accepted the award on behalf of the STAMPEDE trial team. Professor Parmar said: "The STAMPEDE trial's innovative design allows us to achieve answers to questions decades before the more traditional sequential two-arm trial approac ...

STAMPEDE has been shortlisted for the BMJ UK Research Paper of the Year award for the second year in a row; the first to be shortlisted twice for different papers. Now in their 10th year, The BMJ Awards are the UK's leading medical awards. They promote excellence in healthcare and recognise the inspirational work of healthcare teams across the country. This coveted award recognises original research that has the potential to contribute significantly to improving health and health care. MRC CTU at UCL has previously featured at the awards, with wins for ARROW and FEAST, and nominations for STAMPEDE and QUARTZ. A huge amount of work goes on within hospitals and the central coordinating centre across the length of a trial. The nomination is a timely reminder of the nature of these large collaborative projects, which typically run over many years. The shortlisted paper is titled 'Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.' "Abiraterone not only prolon ...


MRC Clinical Trials Unit at UCL
2nd Floor
90 High Holborn



Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.